EA201892732A1 - ANTI-VIRUS AGENTS FOR THE TREATMENT OF HEPATITIS B - Google Patents

ANTI-VIRUS AGENTS FOR THE TREATMENT OF HEPATITIS B

Info

Publication number
EA201892732A1
EA201892732A1 EA201892732A EA201892732A EA201892732A1 EA 201892732 A1 EA201892732 A1 EA 201892732A1 EA 201892732 A EA201892732 A EA 201892732A EA 201892732 A EA201892732 A EA 201892732A EA 201892732 A1 EA201892732 A1 EA 201892732A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hepatitis
hbv
virus
compounds
treatment
Prior art date
Application number
EA201892732A
Other languages
Russian (ru)
Inventor
Яо-Линг Киу
Хуэй Сао
Ксиаовен Пенг
Вей Ли
Джорден Касс
Ксури Гао
Мейжонг Джин
Ят Сун Ор
Original Assignee
Энанта Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Энанта Фармасьютикалз, Инк. filed Critical Энанта Фармасьютикалз, Инк.
Priority claimed from PCT/US2017/036553 external-priority patent/WO2017214395A1/en
Publication of EA201892732A1 publication Critical patent/EA201892732A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Изобретение раскрывает соединения формулы (I) или их фармацевтически приемлемые соликоторые ингибируют белок (белки), кодируемый вирусом гепатита B (ВГВ), или мешают жизненному циклу ВГВ вируса гепатита B, а также являются полезными в качестве противовирусных средств. Данное изобретение дополнительно относится к фармацевтическим композициям, содержащим вышеупомянутые соединения, для введения субъектам, инфецированным ВГВ. Изобретение также относится к способам лечения инфекции ВГВ у субъектов путем введения фармацевтической композиции, содержащей соединения по данному изобретению.The invention discloses compounds of formula (I) or their pharmaceutically acceptable salts inhibit the protein (s) encoded by the hepatitis B virus (HBV), or interfere with the HBV life cycle of the hepatitis B virus, and are also useful as antiviral agents. This invention additionally relates to pharmaceutical compositions containing the above compounds for administration to subjects infected with HBV. The invention also relates to methods of treating HBV infection in subjects by administering a pharmaceutical composition comprising the compounds of the invention.

EA201892732A 2017-01-06 2017-06-08 ANTI-VIRUS AGENTS FOR THE TREATMENT OF HEPATITIS B EA201892732A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762443245P 2017-01-06 2017-01-06
PCT/US2017/036553 WO2017214395A1 (en) 2016-06-10 2017-06-08 Hepatitis b antiviral agents

Publications (1)

Publication Number Publication Date
EA201892732A1 true EA201892732A1 (en) 2019-05-31

Family

ID=66644969

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892732A EA201892732A1 (en) 2017-01-06 2017-06-08 ANTI-VIRUS AGENTS FOR THE TREATMENT OF HEPATITIS B

Country Status (1)

Country Link
EA (1) EA201892732A1 (en)

Similar Documents

Publication Publication Date Title
PH12018550201A1 (en) Hepatitis b antiviral agents
PH12018550148A1 (en) Hepatitis b antiviral agents
PH12018550150A1 (en) Elimination of hepatitis b virus with antiviral agents
CO2021008055A2 (en) Heterocycles functionalized as antiviral agents
EA202090514A1 (en) ANTI-VIRAL AGAINST HEPATITIS IN
UY37998A (en) ANTIVIRAL AGENTS AGAINST HEPATITIS B
UY37997A (en) ANTIVIRAL AGENTS AGAINST HEPATITIS B
WO2019143902A3 (en) Substituted heterocycles as antiviral agents
EA201891876A1 (en) TETRACYCLIC PYRIDONE COMPOUNDS AS ANTI-VIRUS MEANS
EA201791872A1 (en) POLYCYCLIC CARBAMOILPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL APPLICATIONS
EA201591702A1 (en) COMBINATION OF TWO ANTI-VIRAL PREPARATIONS FOR THE TREATMENT OF HEPATITIS C
EA201391519A1 (en) 2'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF THEIR USE FOR THE TREATMENT OF VIRAL DISEASES
MX2021003253A (en) Functionalized heterocycles as antiviral agents.
EA201201031A1 (en) HEPATITIS C VIRUS INHIBITORS
BR112015024552A2 (en) compounds of formula (a), pharmaceutical composition, methods for preparing the compound and methods of treating or preventing infections
EA201591328A1 (en) HETEROCYCLED SUBSTITUTED TETRICYCLIC COMPOUNDS AND METHODS OF THEIR USE FOR THE TREATMENT OF VIRAL DISEASES
EA201591701A1 (en) COMBINATION OF ANTI-VIRAL DIRECT ACTION AND RIBAVIRIN FOR THE TREATMENT OF PATIENTS WITH HCV
EA202192512A1 (en) FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR HBV DISEASES
EA202091113A1 (en) NEW HIGHLY ACTIVE AMINOTHIAZOL SUBSTITUTED INDOL-2-CARBOXAMIDES ACTIVE AGAINST HEPATITIS B VIRUS (HBV)
RU2015114543A (en) HEPATITIS TREATMENT METHODS
PH12021550632A1 (en) Monomer and multimeric anti-hbv agents
MX2022006742A (en) Use and pharmaceutical composition of phenylisoxazolyl methylene-naphthalene-ether derivatives.
WO2021055425A3 (en) Functionalized heterocycles as antiviral agents
EA201001748A1 (en) COMPOUNDS USED FOR THE TREATMENT OF HEPATITIS C
EA201892732A1 (en) ANTI-VIRUS AGENTS FOR THE TREATMENT OF HEPATITIS B